COVID-19, Endothelial Function and Hypertension

  • Research type

    Research Study

  • Full title

    An observational study, investigating the impact of COVID-19 on endothelial and neurovascular function in patients with pre-existing Hypertension

  • IRAS ID

    292957

  • Contact name

    Barry McDonnell

  • Contact email

    bmcdonnell@cardiffmet.ac.uk

  • Sponsor organisation

    Cardiff Metropolitan University

  • Duration of Study in the UK

    0 years, 8 months, 31 days

  • Research summary

    During the current COVID-19 pandemic, there has been debate regarding the use of Angiotensin-Converting Enzyme inhibitors (ACEi) as a treatment for hypertensive patients because of angiotensin-converting enzyme receptor’s role in respiratory disease as well as hypertension. Although the treatment of hypertension with ACEi in patients with COVID-19 has not shown any relationship to increased death rates, several reports have associated damage to the inner layer of arteries – called the endothelium – and rates stroke with COVID-19. This raises the possibility of altered large artery and brain function in those hypertensive patients surviving COVID-19. However, at present, the effects of endothelial damage on patients’ arteries and brain function following recovery from COVID-19 in hypertension patients on ACEi therapy remains unknown. Therefore, this observational study will investigate the impact of a previous COVID-19 infection on peripheral artery and brain function in hypertensive patients on ACEi. Hypertensive patients with a previous COVID-19 diagnosis will be assessed between 4-6 months’ post-recovery, before and after taking their daily anti-hypertension treatment (ACEi) and compared to hypertension patients without previous COVID-19. Peripheral artery function and brain function will be assessed using non-invasive ultrasound and MRI, respectively. The findings will provide an indication of the potential long-term damage caused by COVID-19 on peripheral artery and brain function, in hypertensive patients on ACEi.

  • REC name

    Wales REC 6

  • REC reference

    21/WA/0129

  • Date of REC Opinion

    27 May 2021

  • REC opinion

    Further Information Favourable Opinion